Original Article

The assessment of thyroid autoantibody levels in euthyroid polycystic ovary syndrome patients

Hepşen et al. Thyroid autoantibody levels in PCOS

Sema Hepşen¹, Melia Karaköse², Erman Çakal¹, Sanem Öztekin¹, İlknur Ünsal¹, Pınar Akhanlı¹, Bekir Uçan¹, Mustafa Özbek¹

¹Department of Endocrinology and Metabolism, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
²Department of Endocrinology and Metabolism, Sivas Numune Hospital, Sivas, Turkey
³Department of Internal Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

Received: 11 January, 2018
Accepted: 23 April, 2018

Address for Correspondence: Sema Hepşen
e.mail: semahepsen@gmail.com ORCID ID: orcid.org/0000-0002-8375-7409

Abstract

Objective: Thyroid hormone abnormalities are commonly seen in polycystic ovary syndrome (PCOS) and have considerable effects on comorbidities. The association with PCOS and thyroid autoimmunity which lead to thyroid pathologies are not revealed clearly. We targeted to commentate anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG) antibody levels and thyroid autoimmunity in PCOS.

Material and Methods: 184 patients who got the diagnosis of PCOS regard to the revised 2003 Rotterdam criteria were embodied in this study. 106 age-matched female volunteers were included in the control group. Characteristics, biochemical parameters, thyroid hormone and autoantibody levels of groups were investigated.

Results: Although; we did not find out a statistically significant difference in TSH and sT4 levels between two groups (p>0.05), anti-TPO and anti-TG antibody levels were determined higher in PCOS group significantly (p<0.001). Anti-TPO Ab and anti-TG Ab positivity prevalence of PCOS patients were significantly higher as against to controls (p<0.001; p=0.01).

Conclusion: Not only thyroid hormone levels but also thyroid autoantibody levels should be screened during the investigation of PCOS and the patients with positive results need to be followed up carefully in the long run. (J Turk Ger Gynecol Assoc)

Keywords: Polycystic ovary syndrome, autoimmunity, anti-thyroid peroxidase antibody, anti-thyroglobulin antibody

Introduction

Polycystic ovary syndrome (PCOS) is a prevalent endocrinologic disorder affect women at the fertility period (1). PCOS is identified with menstrual irregularity, hyperandrogenism, and infertility (2). Obesity, metabolic syndrome, dyslipidemia, insulin resistance, type 2 diabetes mellitus, and cardiovascular disorders are the most common comorbidities related to this syndrome (3,4,5,6).

Autoimmune thyroid disease prevalence in women is 4% and rises up to 15% in the event of existing thyroid autoantibody positivity (7). Thyroid hormone dysfunctions and thyroid autoimmunity cause abnormalities on sex hormone metabolism, menstrual irregularities and consequently infertility (8,9).

Anti-thyroid peroxidase antibodies (anti-TPO Ab) and anti-thyroglobulin antibodies (anti-TG Ab) are fundamental markers of thyroid autoimmunity. A study by Bellver J et al. demonstrated that thyroid autoantibodies are significantly higher in infertile patients (8). Close follow up of thyroid hormones are considered important in patients with PCOS because of being the most common reason of medically treatable infertility (10). The latest studies revealed that autoimmune thyroid diseases have an increased prevalence in PCOS patients. (11,12). From this point of view, not only thyroid hormones are substantial for PCOS follow-up but also thyroid antibodies can be guiding for probable thyroid diseases.

The target of this study is to assess thyroid autoantibodies and thyroid hormone levels in PCOS patients by taking into consideration with present or probable thyroid hormone dysfunctions can affect patient's clinical conditions and fertility substantially.

Material and Methods

Our study includes 184 patients who got PCOS diagnose in regard to the revised 2003 Rotterdam criteria at the Endocrinology and Metabolism and Internal Medicine departments of our institution between January 2014-
April 2015 (13). The definition criteria include at least two of the three following subheadings after exclusion of related disorders; oligo or anovulation, clinical and/or biochemical signs of hyperandrogenism and ultrasonographic demonstration of polycystic ovary appearance (13).

106 age-matched healthy female volunteers who menstruate regularly were included in the study as the control group. Individuals who have the diagnosis as hyperprolactinemia, congenital adrenal hyperplasia, androgen-secreting tumours, Cushing syndrome, hypertension, hepatic or renal insufficiency, diabetes mellitus and concurrent thyroid dysfunction were excluded from the study. Being in pregnancy or breastfeeding period and using drugs which affect glucose tolerance and lipid levels were other exclusion criterias. The age range was between 18-41 for all participants. The study protocol was granted by the Ethics Department and each individual signed a written informed consent form. Clinical and anthropometric data including body mass index (BMI) and waist/hip ratio (WHR) were ascertained for each participant.

Biochemical parameters of all individuals were studied after 12 hours fasting at 2th-5th days of the follicular phase. Chemiluminescent immunoassay method was used to assess fasting blood glucose levels (Advia Centaur XP, Siemens Healthcare Diagnostic Inc., Tarrytown USA). The serum insulin levels were studied by electrochemiluminescent immunoassay method (Elecsys 2010, Cobas, Roche Diagnostic, Mannheim, Germany) and free T4 (fT4) levels were quantified via chemiluminescent microparticle immunoassay (Abbott, Architect i2000, Abbott Laboratories Diagnosis Division, IL, USA). Chemical kinetic competitive immunoassay (Advia Centaur XP, Siemens, Tarrytown, USA) was used for the measurement of anti-thyroglobulin antibody (anti-TG Ab) and anti-thyroid peroxidase antibody (anti-TPO Ab) levels. Reference range was as follows for each: TSH: 0.35-4.94 μIU/ml, fT4: 0.7-1.48 ng/dl, anti-TG: 0-60 U/ml, anti-TPO: 0-57 U/ml. Levels above the upper limits of anti-TPO Ab and anti-TG Ab were considered as positive.

Carotid intima-media thickness (CIMT) was estimated by the noninvasive high-resolution ultrasound of the common carotid arteries (Hitachi, Japan; EUB 7000) with 13 MHz linear probe. The carotid intima-media thickness was defined as the distance between the blood-intima and media-adventitia boundaries and the mean value of consecutive three measurements was taken baseline for CIMT. Measurements were carried out from the localization of 1-centimeter distance after the internal carotid arterial bifurcation, where the hemodinamia had been affected minimum, on B-mode imaging. The same researcher performed all measurements.

Statistical analysis

The statistical analysis was carried out with the SPSS statistical software (version 18; SPSS, Chicago, IL, USA). Kolmogorov–Smirnov analysis was done to access normality of the variables. Sample t-tests and Mann Whitney U test was used for the comparison of two group’s distributed variables. Continuous variables were tested by Pearson correlation coefficient and Spearman’s rho correlation coefficient test was done to assess the non-normally distributed variables. P values of < 0.05 were determined statistically significant.

Results

184 patients with PCOS and 106 controls were recruited in the study. Mean age was 23.9± 5.6 for PCOS group and 24.3 ± 4.3 for controls, (p>0.05). BMI, waist-hip ratio, fasting blood glucose, fasting insulin, HOMA-IR, triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and CIMT were higher in PCOS patients (p<0.001, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001, p<0.01 respectively). We didn’t find a significant difference in total cholesterol levels (TC) between two groups (p=0.05), High-density lipoprotein cholesterol (HDL-C) was found lower in PCOS group significantly (p<0.001). Principal data of two groups were represented in Table 1. CIMT had a positive correlation with BMI (r=0.350), waist-hip ratio (p=0.023; r=0.194), HOMA-IR (p<0.001; r=0.310) and a negative correlation with HDL-C levels (p<0.01; r= -0.215) (Table 4).

We did not determine a statically significant difference in TSH and fT4 between the groups (p>0.05). We defined that anti-TPO Ab and anti-TG Ab levels were higher in PCOS group in contrast with controls significantly (p<0.001). Thyroid function tests belong to two groups were demonstrated in Table 2. Anti-TPO Ab was positive in 55 (37.9%) subjects of PCOS group and 11 (11.1%) subjects of controls (Table 3). As also, subjects with positive anti-TG Ab were 22 (15.3%) in PCOS group and 5 (5.1%) in controls (Table 3). Odd’s ratio was calculated as 4.88 for anti-TPO Ab positivity (Confidence Interval 95%=[2.40-9.95]) and 3.39 for anti-TG Ab positivity (Confidence Interval 95%=[1.24-9.28]) (Table 3). Anti-TPO Ab and anti-TG Ab positivity prevalence were determined significantly higher in PCOS patients (respectively; p<0.001, p=0.013) (Table 3). We did not ascertain any correlation between thyroid autoantibody levels and BMI, waist-hip ratio, CIMT and other biochemical parameters.

Discussion

PCOS is the most common reason for medically treatable anovulatory dysfunction (10). Therefore, accurate diagnosis, treatment, and follow-up are substantially important in this patient group. Thyroid function tests are one of the primary studies in the evaluation of menstrual dysfunctions and concurrent thyroid abnormalities for the correct diagnosis of PCOS.
Infertility is a difficult issue in PCOS patients. Thyroid autoimmunity is associated with infertility, miscarriage, complications as gestational hypertension, preeclampsia, pre-term delivery, postpartum haemorrhage and lower probable thyroid disorders during pregnancy and in the postpartum period (7). This disorders may also cause controls. Carotid intima-media thickness is an important identifier for premature atherosclerosis and different studies confirmed that CIMT is significantly higher in PCOS patients who have an increased risk for cardiovascular morbidities (20, 21). In our study, CIMT was statically significant higher in PCOS patients and had a positive correlation with BMI, waist/hip ratio, and HOMA-IR similarly.

Obesity is a metabolic disorder associated with PCOS with the prevalence of 35-70% (17). Many studies concluded that PCOS patients have higher fasting plasma glucose, HOMA-IR, LDL-C, TG and lower HDL-C levels (5, 6, 18, 19). We determined that BMI, waist-hip ratio, fasting blood glucose, fasting insulin, HOMA-IR, triglyceride and LDL-C levels are higher; HDL-C level was lower significantly in PCOS group as against to controls. Carotid intima-media thickness is an important identifier for premature atherosclerosis and different studies confirmed that CIMT is significantly higher in PCOS patients who have an increased risk for cardiovascular morbidity (20, 21). In our study, CIMT was statically significant higher in PCOS patients and had a positive correlation with BMI, waist/hip ratio, and HOMA-IR similarly.

Infertility is a difficult issue in PCOS patients. Thyroid autoimmunity is associated with infertility, miscarriage, probable thyroid disorders during pregnancy and in the postpartum period (7). This disorders may also cause complications as gestational hypertension, preeclampsia, pre-term delivery, postpartum haemorrhage and lower birth weight (9). Poppe K et al. reported that TSH and anti-TPO antibodies are significantly higher in infertile patients with different reasons (endometriosis, tubal and ovarian pathologies) (8). Another study demonstrated that autoimmune thyroid disease prevalence in infertile women is 16% and statically significantly higher than controls (22). Bellver J et al. represented that autoimmune thyroid disease is higher in PCOS patients and have a strong correlation with unexplained infertility and implantation failure (23). Ott J et al. also pointed out the relationship between PCOS patients with higher anti-TPO levels and insufficient therapy response in infertile patients who administered clomiphene citrate and metformin (24).

In conclusion; we showed that thyroid autoantibody positivity prevalence of euthyroid PCOS patients is 3.5 times higher with respect to control group. Although thyroid hormone level evaluation is fundamental for PCOS follow-up and treatment, thyroid autoantibody assessment is mostly neglected. From all these close relations with PCOS and thyroid dysfunctions, we suggest evaluating both thyroid autoantibodies and hormone levels in PCOS patients at the initial visit and euthyroid patients with positive results for autoantibodies should be followed up closely for the possible thyroid disorders and relevant complications.

Ethical Committee Approval: Ethics committee approval of this study was assumed from the ethics committee of Dışkapı Yıldırım Beyazıt Training and Research Hospital.

Informed Consent: The written informed consent form was received from all individual participants included in the study.


Conflict of Interest: The authors proclaimed that they have no conflict of interest.

Financial Disclosure: The authors proclaimed that this study derived no financial support.

References
Table 1. The clinical and biochemical data of patients with PCOS and controls

<table>
<thead>
<tr>
<th>Variable</th>
<th>PCOS (n=184)</th>
<th>Controls (n=106)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (mean ± SD)</td>
<td>23.9± 5.6</td>
<td>24.3 ± 4.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>BMI, kg/m² (min-max)</td>
<td>26.4 (16-44)</td>
<td>22.1 (16-40.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Waist/hip ratio (min-max)</td>
<td>0.83 (0.41-1.1)</td>
<td>0.73 (0.63-0.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting glucose, mg/dl (mean ± SD)</td>
<td>84 ± 8.6</td>
<td>80 ± 8.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting insulin, IU/ml (min-max)</td>
<td>2.8 (1.2-10)</td>
<td>1.8 (1-6.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA-IR (min-max)</td>
<td>2.85 (0.46-18)</td>
<td>1.85 (0.39-7.32)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl (min-max)</td>
<td>170 (120-286)</td>
<td>166 (121-236)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Triglyceride, mg/dl (min-max)</td>
<td>94 (28-353)</td>
<td>73 (29-216)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C, mg/dl (min-max)</td>
<td>51 (30-97)</td>
<td>59 (33-110)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL-C, mg/dl (min-max)</td>
<td>100 (50-168)</td>
<td>84 (51-136)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CIMT (mm) (min-max)</td>
<td>0.49(0.33-0.66)</td>
<td>0.48(0.33-0.6)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment insulin resistance index; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; CIMT, carotid intima media thickness.

Table 2. Thyroid function test results of groups

<table>
<thead>
<tr>
<th>Variable (min-max)</th>
<th>PCOS (n=184)</th>
<th>Controls (n=106)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH (µIU/ml)</td>
<td>2 (0.34-19.8)</td>
<td>1.8 (0.8-5.6)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>fT4 (ng/ml)</td>
<td>1.1 (0.59-2)</td>
<td>1.1 (0.9-1.46)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Anti-TG (IU/ml)</td>
<td>26 (0.9-524)</td>
<td>20 (10-308)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anti-TPO (IU/ml)</td>
<td>52 (0.2-1300)</td>
<td>10 (10-1000)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: TSH: Thyroid stimulating hormone; fT4: free T4; Anti-TG Ab: Anti-thyroglobulin antibody; Anti-TPO Ab: Anti-thyroid peroxidase antibody.
Table 3. Thyroid autoantibody positivity and odd's ratio for PCOS and control groups

<table>
<thead>
<tr>
<th></th>
<th>PKOS (n=184)</th>
<th>Controls (n=106)</th>
<th>P</th>
<th>Odd ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TG (%)</td>
<td>15.3%</td>
<td>5.1%</td>
<td>0.013</td>
<td>3.39 (1.24-9.28)</td>
</tr>
<tr>
<td>Anti-TPO (%)</td>
<td>37.9%</td>
<td>11.1%</td>
<td>&lt;0.001</td>
<td>4.8 (2.40-9.95)</td>
</tr>
</tbody>
</table>

Abbreviations: Anti-TG Ab: Anti-thyroglobulin antibody; Anti-TPO Ab: Anti-thyroid peroxidase antibody; CI: Confidence Interval.

Table 4. Parameters and their correlations with CIMT

<table>
<thead>
<tr>
<th></th>
<th>P</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>&lt;0.001</td>
<td>0.350</td>
</tr>
<tr>
<td>Waist/hip ratio</td>
<td>0.023</td>
<td>0.194</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>&lt;0.001</td>
<td>0.310</td>
</tr>
<tr>
<td>HDL, mg/dl</td>
<td>&lt;0.01</td>
<td>-0.215</td>
</tr>
</tbody>
</table>

CIMT, carotid intima media thickness; BMI, body mass index; HOMA-IR, homeostasis model assessment insulin resistance index; HDL-C, high density lipoprotein cholesterol.